St. Joseph, MI. – GeneGo, Inc., the leading systems biology tools company, announced today that it launched a collaborative development project on systems biology of stem cells with global pharmaceutical companies and leading academic centers as members. The 24-month project aims to create a comprehensive “knowledge base” on development and biology of different types of stem cells. The knowledge base will be supported by GeneGo’s MetaDiscovery tools and applied in experimental research on stem cells and human diseases.

“We are really excited about this project,” said Yuri Nikolsky, CEO of GeneGo. “Although one of the hottest areas of life science, no systematic effort was done on methodical annotation of current experimental knowledge on stem cells, and we intend to fill this gap. Understanding the biology of embryonic adult and neoplastic stem cells is key in both drug discovery and fundamental research in many fields from embryology and ontogenesis to cancer and diabetes.”

“We are very glad to be able to attract an excellent team of members for the cause,” said Julie Bryant, GeneGo’s VP of Business Development. “An industry-academia consortium model fits well with our development objectives in such a complex and controversial field. We believe that the members will see a strong positive return on their investment within several months from the project’s launch.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscoveryTM platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 5.4TM, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.4TM is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBaseTM represents the knowledge base for MetaCore.

For more information, please visit the company’s web site at www.genego.com.